Transcarent

Summary active Updated Jul 23, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Palo Alto, CA
Founded 2020
Latest Stage Series D
Total Raised $424M

Investors

Glen Tullman Founder/Seed (2021)
Hemant Taneja Founding (2020)
Lee Shapiro Seed (hatched) (2021)
General Catalyst series-a (2020)
7wire Ventures series-a (2020)
General Catalyst series-b (2021)
7wire Ventures series-b (2021)
Kleiner Perkins series-b (2021)

Founders

Glen Tullman Chairman & CEO

About

Transcarent is a Palo Alto-headquartered consumer-directed health and care platform for self-insured employers, hatched by Glen Tullman and Lee Shapiro of 7wireVentures alongside Hemant Taneja of General Catalyst — the same team behind Livongo 123. The company launched publicly in March 2021 after closing its Series A financing in October 2020, which was announced concurrently with the acquisition of BridgeHealth to serve as the foundation of the platform 123. Transcarent achieved unicorn status in 2022 and reached a $2.2 billion valuation with its 2024 Series D 45.

Funding History

Date Round Amount Lead Co-investors
2020-10-22 Series A $40M General Catalyst (Hemant Taneja), 7wireVentures (Lee Shapiro) Alta Partners, Jove Equity Partners 123
2021-06-10 Series B $58M General Catalyst, 7wireVentures Kleiner Perkins, Merck Global Health Innovation Fund, Leaps by Bayer, GreatPoint Ventures, Threshold Ventures, Alta Partners, Jove Equity Partners 6
2024-05-02 Series D $126M 45

The 2024 Series D valued the company at $2.2 billion 45.

What Investors Say

Hemant Taneja, Managing Partner at General Catalyst: “We believe Transcarent will be another game changer…offering their employees a transformative experience across their most common and most important care needs” 1.

What Founders Say

No independently sourced founder testimonials found beyond company press.

Sources


  1. Transcarent, “Glen Tullman Joins Transcarent as Chief Executive Officer,” March 18, 2021. Accessed July 23, 2026. https://transcarent.com/press-releases/glen-tullman-joins-transcarent-as-chief-executive-officer

  2. Forbes, “‘Concierge Medicine On Steroids’ Startup Raised $40 Million To Disrupt Employer-Sponsored Care,” March 18, 2021. Accessed July 23, 2026. https://www.forbes.com/sites/katiejennings/2021/03/18/concierge-medicine-on-steroids-startup-raised-40-million-to-disrupt-primary-care/

  3. Vator News, “Transcarent raises $58M to put patients in control of their own health,” June 10, 2021. Accessed July 23, 2026. https://vator.tv/2021-06-10-transcarent-raises-58m-to-put-patients-in-control-of-their-own-health/

  4. STAT News, “Transcarent, Glen Tullman’s health tech unicorn, raises $126 million,” May 2, 2024. Accessed July 23, 2026. https://www.statnews.com/2024/05/02/glen-tullman-transcarent-health-tech-secures-126-million-investment/

  5. Transcarent, “Transcarent Raises $126 Million Series D,” May 2, 2024. Accessed July 23, 2026. https://transcarent.com/press-releases/transcarent-raises-usd126-million-series-d

  6. BusinessWire, “Transcarent Raises $58 Million in Series B Funding,” June 10, 2021. Accessed July 23, 2026. https://www.businesswire.com/news/home/20210610005315/en/Transcarent-Raises-$58-Million-in-Series-B-Funding-to-Accelerate-Consumer-Directed-Health-and-Care-Experience-for-Self-Insured-Employers